Genentech’s IPF Therapy to Improve Lung Function

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_function

New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time.

The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF),” was made by Dr. Steven Nathan, Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, at the Pulmonary Fibrosis Foundation’s recent PFF Summit 2015, held in Washington, D.C.

 

Read more about it: http://bit.ly/1Q2GWNS

Learn more about How Esbriet Works: http://bit.ly/1Qjbmdb

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums